ORIEN Cancer Data Network Adds Collaborators
News Jul 13, 2015
"Becoming part of ORIEN adds great opportunities for Rutgers Cancer Institute of New Jersey, enabling discovery based on large-scale, diverse population data as well as patient-specific clinical decision support across a broad, national clinical trial portfolio," Robert DiPaola, director of the Rutgers Cancer Institute of New Jersey, said in a statement.
ORIEN was launched in May 2014 by the Moffitt Cancer Center and Ohio State University Comprehensive Cancer Center to bring together data to drive research collaborations in oncology and personalized medicine. With the new additions, the network now has nine members.
In February, City of Hope, University of Virginia Cancer Center, University of Colorado Cancer Center, and University of New Mexico Cancer Center joined ORIEN.
Existing 20-year-old Multiple Sclerosis Drug Effective Against Multi-resistant BacteriaNews
A widely-used and twenty-year-old medicine used to treat multiple sclerosis can also beat a type of multi-resistant bacteria for which there are currently only a few effective drugs.READ MORE
Novel Chemistry Technique Simplifies Late-Stage Modification of Drug CompoundsNews
Chemists at The Scripps Research Institute (TSRI) have invented a technique that overcomes a long-standing problem in organic chemistry and should streamline the process of discovery and development for many new drugs.READ MORE
Dipstick Technology Enables Rapid Diagnosis AnywhereNews
A new Australian study has reported a revolutionary dipstick technology that allows DNA and RNA to be extracted from living organisms in as little as 30 seconds.READ MORE